- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Grant to help fund development of the Bio-Retina, a "bionic retina" designed to restore full sight to the blind
Nano Retina announced today that it has received a grant for just under three-quarters of one million dollars from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation. The financing will be used to further develop the Bio-Retina, a "bionic retina" designed to return full sight to those blinded by retinal degenerative conditions.
The BIRD Foundation acts to encourage collaboration between Israeli and American companies in various fields of technology. Eitan Yudilevich, Ph.D., executive director of the BIRD Foundation said, "Returning sight to those blinded by a retinal degeneration condition is a goal of enormous importance. U.S. and Israeli reviewers thoroughly examined the activity and plans of this exciting and challenging initiative. Nano Retina is combining outstanding U.S. and Israeli human resources and technologies to develop a 'bionic retina', which if successful, will likely change the lives of millions for the better."
Bio-Retina is a tiny implant designed to replace the damaged retina in the eye. The implant's nano-sized components are powered by a special pair of activation eyeglasses. Bio-Retina will be surgically implanted in a minimally invasive, 30-minute procedure, which requires only local anesthesia. Full sight is anticipated instantaneously.
"50,000 people in the United States become blind annually. In addition, there are currently 3.6 million Americans aged 40 and older who are legally blind. Bio-Retina is designed to restore full sight to those blinded by degenerative conditions such as AMD, Diabetes Retinopathy or Retinitis Pigmentosa. By full sight we mean the patient will be able to watch TV and identify faces," said Ra‟anan Gefen, managing director of Nano Retina.
He continued, "We have a working 'electrical' prototype and have demonstrated proof of concept. We intend to use the generous funding from BIRD to miniaturize the system and develop a 'nano' prototype. All of the medical and technology industry experts with whom we have consulted agree that our product development expectations are attainable. We have laid the development foundation and now expect to begin clinical trials in 2012."
About Nano Retina
Nano Retina is a joint venture of Rainbow Medical (www.rainbowmedical.co.il) and Zyvex Labs (www.zyvexlabs.com). Rainbow Medical, headquartered in Herzliya, Israel and backed by worldwide investors, is an operational investment company formed to support the many medical devices invented by visionary Yossi Gross. Zyvex Labs, founded by nano industry icon Jim Von Ehr, is a leading nano technology developer based in Dallas, Texas. Nano Retina is open to collaboration discussions.
For more information, please click here
Copyright © Nano RetinaIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Programmable materials find strength in molecular repetition May 23rd, 2016
NRL reveals novel uniform coating process of p-ALD April 21st, 2016
New ORNL method could unleash solar power potential March 16th, 2016
Nanoscale view of energy storage January 16th, 2017